145 related articles for article (PubMed ID: 37148216)
1. Making a 'sex-difference fact': Ambien dosing at the interface of policy, regulation, women's health, and biology.
Zhao H; DiMarco M; Ichikawa K; Boulicault M; Perret M; Jillson K; Fair A; DeJesus K; Richardson SS
Soc Stud Sci; 2023 Aug; 53(4):475-494. PubMed ID: 37148216
[TBL] [Abstract][Full Text] [Related]
2. US Food and Drug Administration Office of Women's Health: Promoting Therapeutic Optimization in Women.
South EM; Zinn RL; Huang CJ; Vasisht KP
J Clin Pharmacol; 2020 Dec; 60 Suppl 2():S11-S17. PubMed ID: 33274515
[No Abstract] [Full Text] [Related]
3. The Food and Drug Administration Office of Women's Health: impact of science on regulatory policy.
Obias-Manno D; Scott PE; Kaczmarczyk J; Miller M; Pinnow E; Lee-Bishop L; Jones-London M; Chapman K; Kallgren D; Uhl K
J Womens Health (Larchmt); 2007; 16(6):807-17. PubMed ID: 17678451
[TBL] [Abstract][Full Text] [Related]
4. US Food and Drug Administration office of women's health: update.
Sheppard A
J Am Med Womens Assoc (1972); 1999; 54(2):97-8. PubMed ID: 10319599
[TBL] [Abstract][Full Text] [Related]
5. Women's health advocates dismayed at FDA's Plan B decision.
Ready T
Nat Med; 2005 Oct; 11(10):1016. PubMed ID: 16211017
[No Abstract] [Full Text] [Related]
6. The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.
Elahi M; Eshera N; Bambata N; Barr H; Lyn-Cook B; Beitz J; Rios M; Taylor DR; Lightfoote M; Hanafi N; DeJager L; Wiesenfeld P; Scott PE; Fadiran EO; Henderson MB
J Womens Health (Larchmt); 2016 Mar; 25(3):222-34. PubMed ID: 26871618
[TBL] [Abstract][Full Text] [Related]
7. FDA's decision on Plan B: a surrogate for lack of commitment to women's health.
Merkatz RB
J Womens Health (Larchmt); 2005 Nov; 14(9):860. PubMed ID: 16313214
[No Abstract] [Full Text] [Related]
8. Gender-based differences in the toxicity of pharmaceuticals--the Food and Drug Administration's perspective.
Miller MA
Int J Toxicol; 2001; 20(3):149-52. PubMed ID: 11488556
[TBL] [Abstract][Full Text] [Related]
9. Office of Women's Health, Food and Drug Administration: future directions for women's health.
Wood SF
J Am Med Womens Assoc (1972); 2001; 56(4):197-8. PubMed ID: 11759792
[TBL] [Abstract][Full Text] [Related]
10. Feminism and regulation collide: the Food and Drug Administration's approval of the cervical cap.
Gallagher DM; Richwald GA
Women Health; 1989; 15(2):87-97. PubMed ID: 2781812
[TBL] [Abstract][Full Text] [Related]
11. Patient Experience Data in US Food and Drug Administration (FDA) Regulatory Decision Making:: A Policy Process Perspective.
Kuehn CM
Ther Innov Regul Sci; 2018 Sep; 52(5):661-668. PubMed ID: 29714560
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of worldwide clinical trials by gender: An FDA perspective.
Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
[TBL] [Abstract][Full Text] [Related]
13. Women's health and the FDA.
Wood SF
N Engl J Med; 2005 Oct; 353(16):1650-1. PubMed ID: 16236734
[No Abstract] [Full Text] [Related]
14. Does exclusion or inclusion better protect women?
Shultz MM
J Gend Specif Med; 1998; 1(2):18-22. PubMed ID: 11281007
[No Abstract] [Full Text] [Related]
15. Sex as a Biological Variable: A 5-Year Progress Report and Call to Action.
Arnegard ME; Whitten LA; Hunter C; Clayton JA
J Womens Health (Larchmt); 2020 Jun; 29(6):858-864. PubMed ID: 31971851
[TBL] [Abstract][Full Text] [Related]
16. Working Together to Address Women's Health in Research and Drug Development: Summary of the 2017 Women's Health Congress Preconference Symposium.
Feuerstein IM; Jenkins MR; Kornstein SG; Lauer MS; Scott PE; Raju TNK; Johnson T; Devaney S; Lolic M; Henderson M; Clayton JA
J Womens Health (Larchmt); 2018 Oct; 27(10):1195-1203. PubMed ID: 30325292
[TBL] [Abstract][Full Text] [Related]
17. FDA lifts ban on women in early drug tests, will require companies to look for gender differences.
Cotton P
JAMA; 1993 Apr; 269(16):2067. PubMed ID: 8468748
[No Abstract] [Full Text] [Related]
18. The evolution of FDA policy on silicone breast implants: a case study of politics, bureaucracy, and business in the process of decision-making.
Palley HA
Int J Health Serv; 1995; 25(4):573-91. PubMed ID: 8575864
[TBL] [Abstract][Full Text] [Related]
19. Educating the Scientific Workforce on Sex and Gender Considerations in Research: A National Scan of the Literature and Building Interdisciplinary Research Careers in Women's Health Programs.
Libby AM; McGinnes HG; Regensteiner JG
J Womens Health (Larchmt); 2020 Jun; 29(6):876-885. PubMed ID: 32456574
[No Abstract] [Full Text] [Related]
20. Gender matters: an integrated model for understanding men's and women's health.
Bird CE; Rieker PP
Soc Sci Med; 1999 Mar; 48(6):745-55. PubMed ID: 10190637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
